LEXINGTON, Mass.--(BUSINESS WIRE)--Headline of release should read ...HMGB1 Preclinical Programs (sted ...HMGB1 Preclincial Programs) The corrected release reads: CRITICAL THERAPEUTICS ANNOUNCES THE ISSUANCE OF FOUR NEW PATENTS FOR ITS ALPHA-7 AND HMGB1 PRECLINICAL PROGRAMS Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the issuance of four new U.S. patents during 2007 that strengthen the Company’s intellectual property protecting its two pre-clinical programs, alpha-7 nicotinic acetylcholine receptor (Alpha-7) and High Mobility Group Box 1 (HMGB1). The patents relate to methods and molecules that act as agonists of the Alpha-7 receptor, or target the HMGB1 protein, to treat inflammatory disease.
